Deep-dive briefing

Thu · 3 Sep 2026

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.

Phase 2 Evidence and Impact Analysis

All 65 articles reviewed. Scores reflect independent Phase 2 judgment applied to Phase 1 triage metadata. Articles assessed as abstract-only throughout.

Article 1 — PMID 42686628

Non-pharmacological delirium prevention RCT (ICU)

Dimension	Score	Rationale
Scientific Novelty	4	Non-pharmacological bundles (ABCDEF) are established; cluster RCT design adds rigor, but concept is not new
Clinical Relevance	6	Delirium is a major ICU complication; nurse-driven protocols are implementable
Population Reach	6	Millions of ICU admissions annually; effect generalizable if confirmed
Implementation Speed	6	No new drug needed; workflow change is feasible
Evidence Strength	6	Cluster RCT is appropriate design; n=474 moderate; abstract-only, French-language journal limits appraisal

Quantitative result: Not extractable from abstract (French language, abstract only) External validation: Single-protocol trial; no external replication noted Main limitation: Abstract only; French language limits full assessment; cluster RCT design susceptible to contamination bias Equity: Potentially benefits all ICU patients; resource-constrained settings may struggle with protocol implementation Evidence Maturity Revision: Exploratory → Potentially Practice-Confirming (the concept is validated; this trial adds implementation evidence)

Phase 2 Composite Score: (6×0.30) + (6×0.25) + (4×0.20) + (6×0.15) + (6×0.10) = 5.80 Original triage_score: 8 (inflated by sentinel scan; Phase 2 downward correction appropriate)

Article 2 — PMID 42686461

RFA vs. laparoscopic resection for small HCC in elderly — multicenter propensity-matched study

Dimension	Score	Rationale
Scientific Novelty	5	RFA vs. resection debate is ongoing; propensity matching in elderly subgroup adds incremental value
Clinical Relevance	7	Direct treatment comparison for a real clinical decision; elderly patients are underserved in trial populations
Population Reach	6	HCC incidence rising globally; elderly population particularly affected
Implementation Speed	7	RFA is already available; results could shift practice quickly for appropriate patients
Evidence Strength	4	Propensity-matched retrospective; n=102 (only 51 per arm post-matching); classification_confidence = medium; abstract only

Quantitative result: Comparable OS between arms; RFA: significantly lower morbidity, faster recovery; RFA preferred for tumors ≤2 cm or high-surgical-risk External validation: Multicenter design adds some generalizability; not externally validated Main limitation: Small sample (n=102), retrospective propensity matching, selection bias risk, abstract only Equity: Benefits elderly patients often excluded from surgical trials — meaningful underserved population signal Evidence Maturity Revision: Exploratory (confirmed; small n, retrospective)

Phase 2 Composite Score: (7×0.30) + (6×0.25) + (5×0.20) + (7×0.15) + (4×0.10) = 5.95 Original triage_score: 8 (overcalled; Phase 2 correction to ~6)

Article 3 — PMID 42685984

HCC Surveillance: Abbreviated MRI, Biomarkers, Benefit Stratification — Review/Perspective 🔴

Dimension	Score	Rationale
Scientific Novelty	6	Synthesizes emerging evidence including ongoing PREMIUM RCT; abbreviated MRI as screening modality is novel compared to standard US+AFP
Clinical Relevance	7	Directly informs surveillance strategy for millions with cirrhosis; benefit stratification is clinically actionable
Population Reach	8	~100M people globally with cirrhosis; HCC a leading cause of cancer death
Implementation Speed	5	Awaiting PREMIUM RCT results; policy change likely 3–5 years out
Evidence Strength	4	Review/perspective; no primary outcome data; abstract only; references ongoing but incomplete RCT

Quantitative result: No primary data presented (review article referencing ongoing PREMIUM RCT) External validation: N/A — synthesizes existing studies Main limitation: Not a primary study; key trial (PREMIUM) results pending; abstract-only access Equity: Patients in low-resource settings may not have MRI access — notable access equity gap Evidence Maturity Revision: Validated (evidence synthesis is mature; practice change contingent on PREMIUM results)

Phase 2 Composite Score: (7×0.30) + (8×0.25) + (6×0.20) + (5×0.15) + (4×0.10) = 6.50 Original triage_score: 7

Article 4 — PMID 42686451

CAR-T (Axi-cel) vs. Allo-HCT for r/r LBCL — Cohort Study 🟠

Dimension	Score	Rationale
Scientific Novelty	5	Axi-cel superiority over allo-HCT has been suggested in prior studies (e.g., ZUMA-7); this adds real-world confirmation
Clinical Relevance	8	Directly informs a high-stakes treatment decision: CAR-T vs. stem cell transplant for relapsed lymphoma
Population Reach	6	~20,000 new r/r LBCL cases/year in US; globally significant
Implementation Speed	6	CAR-T approved; allo-HCT established — findings actionable if confirmed, but availability gaps exist
Evidence Strength	5	Cohort study, n=187; propensity matching not explicitly mentioned; abstract only; real-world confounding risk

Quantitative result: Axi-cel superior PFS and OS vs. allo-HCT; mechanism = lower treatment-related mortality + better disease control in chemorefractory patients External validation: Consistent with ZUMA-7 RCT direction but this is observational Main limitation: Observational cohort; selection bias (patients selected for axi-cel may be fitter); n=187; abstract only Equity: CAR-T access highly unequal globally and even within high-income countries — critical equity concern Evidence Maturity Revision: Validated (confirmed — consistent with randomized evidence stream)

Phase 2 Composite Score: (8×0.30) + (6×0.25) + (5×0.20) + (6×0.15) + (5×0.10) = 6.40 Original triage_score: 7

Article 5 — PMID 42686030

3D-Printed Guides vs. Navigation vs. Robotic Assistance in Spinal Instrumentation — NMA

Dimension	Score	Rationale
Scientific Novelty	4	Network meta-analysis synthesizing existing comparative data; technology comparison is ongoing debate
Clinical Relevance	6	Pedicle screw accuracy directly affects surgical outcomes and complication rates
Population Reach	5	Spinal surgery is common but specialized
Implementation Speed	5	Technologies already exist; adoption depends on cost and training
Evidence Strength	5	Systematic review/NMA is strong design; n=133 studies (not patients) suggests broad but heterogeneous evidence base; abstract provides truncated finding

Quantitative result: ROM 0.[truncated] — finding incomplete; 3D guides appear superior in some metrics vs. navigation and robotic assistance External validation: NMA design inherently synthesizes multiple studies Main limitation: Incomplete key finding extraction; network meta-analysis assumes transitivity; heterogeneity likely; abstract only Equity: Cost of 3D printing vs. robotics may favor 3D guides in lower-resource settings — potential equity benefit Evidence Maturity Revision: Potentially Practice-Changing (confirmed)

Phase 2 Composite Score: (6×0.30) + (5×0.25) + (4×0.20) + (5×0.15) + (5×0.10) = 5.30 Original triage_score: 7 (somewhat overcalled; misclassified under hematologic malignancies — unrelated topic)

Article 6 — PMID 42685840

Soluble PD-1/PD-L1 Biomarkers in NSCLC — Review

Dimension	Score	Rationale
Scientific Novelty	6	sPD-L1 as liquid biopsy complement to tissue IHC is conceptually novel; adds real-time monitoring angle
Clinical Relevance	6	Could reduce need for repeat biopsies and improve immunotherapy patient selection
Population Reach	7	NSCLC is among the most common cancers globally; ~250,000 new US cases/year
Implementation Speed	4	Blood-based assays need standardization and clinical validation trials before routine use
Evidence Strength	3	Cross-sectional review, no sample size, classification_confidence = medium; abstract only

Quantitative result: sPD-L1 = negative predictor of therapeutic efficacy and surgical durability; sPD-1 tracks T-cell clonal reactivation on treatment External validation: Review synthesis; no single prospective validation Main limitation: Cross-sectional review design; no prospective validation; assay standardization absent; abstract only Equity: Blood-based testing more accessible than tissue biopsy in low-resource settings — equity positive if validated Evidence Maturity Revision: Exploratory (confirmed)

Phase 2 Composite Score: (6×0.30) + (7×0.25) + (6×0.20) + (4×0.15) + (3×0.10) = 5.65 Original triage_score: 7

Article 7 — PMID 42685528

Determinants of Lung Cancer Screening Intention

Dimension	Score	Rationale
Scientific Novelty	3	Barriers to LCS well-documented; sociodemographic/access factors are known predictors
Clinical Relevance	5	Informs outreach but doesn't change clinical practice directly
Population Reach	7	8–10M LCS-eligible adults in US alone; findings broadly applicable
Implementation Speed	6	Behavioral and access interventions can be deployed relatively quickly
Evidence Strength	5	Cross-sectional survey; n=521; self-reported intention (not behavior); abstract only

Quantitative result: Screening intention limited among never-screened eligible adults; associated with sociodemographic characteristics, healthcare access, and cancer beliefs External validation: Consistent with prior literature on LCS uptake barriers Main limitation: Self-reported intent ≠ actual screening behavior; cross-sectional; single time-point; abstract only Equity: Central finding IS an equity finding — lower-access, lower-SES groups less likely to intend screening Evidence Maturity Revision: Exploratory (confirmed)

Phase 2 Composite Score: (5×0.30) + (7×0.25) + (3×0.20) + (6×0.15) + (5×0.10) = 5.20 Original triage_score: 7

Article 8 — PMID 42685390

Household Food Insecurity and Cancer — Systematic Review and Meta-Analysis

Dimension	Score	Rationale
Scientific Novelty	5	First comprehensive meta-analysis on HFI-cancer link; novel synthesis despite intuitive direction
Clinical Relevance	6	Identifies modifiable systemic barrier; informs oncology social work and policy
Population Reach	9	>800M food-insecure people globally; cancer affects all populations — intersection is enormous
Implementation Speed	3	Policy-level change required; slow to implement at scale
Evidence Strength	6	Systematic review/meta-analysis; n=1,135,888 — very large pooled sample; observational base limits causal inference; abstract only

Quantitative result: HFI acts as barrier to screening, treatment adherence, and survivorship — contributing to cancer outcome inequities External validation: Meta-analysis inherently aggregates; quality depends on constituent study heterogeneity Main limitation: Observational base; cannot establish causality; heterogeneity across study settings likely; abstract only Equity: This IS an equity study — food-insecure populations are the underserved group; findings directly relevant to reducing disparities Evidence Maturity Revision: Potentially Practice-Changing (confirmed — policy and clinical implications are meaningful)

Phase 2 Composite Score: (6×0.30) + (9×0.25) + (5×0.20) + (3×0.15) + (6×0.10) = 6.00 Original triage_score: 7

Article 9 — PMID 42684344

Epigenetic Liquid Biopsy for NSCLC — Study Protocol 🔴

Dimension	Score	Rationale
Scientific Novelty	7	Integrated genomic + epigenomic + transcriptomic liquid biopsy in a single NSCLC cohort is genuinely novel
Clinical Relevance	5	Protocol paper only — no results yet; potential is high but speculative
Population Reach	7	NSCLC is global top-3 cancer killer; liquid biopsy could replace/complement tissue biopsy
Implementation Speed	3	Study not yet completed; clinical translation likely 5–10 years
Evidence Strength	3	Protocol paper (no results); cohort design; abstract only; classification_confidence = high but for a protocol

Quantitative result: None — protocol paper External validation: None yet Main limitation: No results available; single-country (New Zealand) cohort; generalizability unknown; abstract only Equity: If validated, liquid biopsy reduces need for invasive tissue sampling — equity benefit in resource-limited settings Evidence Maturity Revision: Reclassify to Exploratory (it is a protocol, not validated results; Phase 1 "Validated" label was incorrect)

Phase 2 Composite Score: (5×0.30) + (7×0.25) + (7×0.20) + (3×0.15) + (3×0.10) = 5.20 Original triage_score: 7 (appropriate for flag; score reflects protocol-stage reality)

Article 10 — PMID 42684491

Cornea-Specialized LLM with RAG for Diagnostic Accuracy — RCT

Dimension	Score	Rationale
Scientific Novelty	7	Domain-specialized LLM + RAG in a clinical RCT is genuinely novel; tests real workflow integration
Clinical Relevance	6	Improves accuracy specifically for less-experienced clinicians — meaningful for training and access
Population Reach	4	Corneal disease is important but specialty-limited; broader LLM-assist principle is generalizable
Implementation Speed	6	LLM tools deployable quickly if validated; regulatory pathway unclear
Evidence Strength	6	RCT design; no sample size reported; abstract only; single specialty application

Quantitative result: Improved diagnostic accuracy in complex corneal cases; greatest benefit for clinicians with lower baseline performance External validation: Single RCT; no external replication; novel study design Main limitation: No sample size; abstract only; single specialty; generalizability of RAG-LLM approach needs multi-site validation Equity: Could narrow expertise gap between urban academic centers and rural/underserved clinicians Evidence Maturity Revision: Potentially Practice-Changing (confirmed — RCT evidence for AI decision support is important)

Phase 2 Composite Score: (6×0.30) + (4×0.25) + (7×0.20) + (6×0.15) + (6×0.10) = 5.80 Original triage_score: 7

Article 11 — PMID 42684280

Two-Plane AI Renal Ultrasound for Hydronephrosis Grading in Infants

Dimension	Score	Rationale
Scientific Novelty	6	Two-plane AI workflow simplification for renal grading is novel; pediatric imaging AI underdeveloped
Clinical Relevance	5	Reduces reader dependency in a common pediatric finding; clinical pathway implications
Population Reach	5	Postnatal hydronephrosis affects ~1% of newborns — moderate population
Implementation Speed	6	Ultrasound-based; no new equipment needed if AI integrated into existing systems
Evidence Strength	4	Single-center proof-of-concept; n=79; internal validation only; abstract only

Quantitative result: AI-assisted workflow closely matches expert consensus grading in selected infants External validation: Explicitly "internal validation only" — external validation needed Main limitation: Single center; internal validation; small n; selected patients; abstract only Equity: Standardization could benefit non-specialist centers without ultrasound experts Evidence Maturity Revision: Exploratory (Phase 1 "Validated" was incorrect — internal validation ≠ validated)

Phase 2 Composite Score: (5×0.30) + (5×0.25) + (6×0.20) + (6×0.15) + (4×0.10) = 5.25 Original triage_score: 7

Article 12 — PMID 42684200

AI Models for Suicide Risk Prediction — Retrospective Study

Dimension	Score	Rationale
Scientific Novelty	6	Ensemble AI using multi-source EHR for suicide risk is a notable advance over single-source models
Clinical Relevance	6	Suicide prevention is a major unmet need; EHR-integrated risk tools could change triage
Population Reach	8	Suicide is a global health crisis; mental health patients are high-burden population
Implementation Speed	4	EHR integration, validation, and ethical review needed before deployment
Evidence Strength	4	Retrospective; n=2,764; no prospective validation; specific performance metrics not extractable from abstract

Quantitative result: Multi-source EHR ensemble algorithms developed; specific AUC/performance metrics not reported in abstract External validation: No external validation reported Main limitation: Retrospective; single-system EHR data; no prospective validation; algorithmic bias risk; abstract only Equity: Mental health patients, often underserved; algorithmic bias could exacerbate disparities if not carefully validated across demographic groups Evidence Maturity Revision: Exploratory (confirmed)

Phase 2 Composite Score: (6×0.30) + (8×0.25) + (6×0.20) + (4×0.15) + (4×0.10) = 6.00 Original triage_score: 7

Article 13 — PMID 42686374

Immunotherapy vs. Standard of Care in MSS mCRC Without Liver Metastases — Propensity-Matched Retrospective ⚪

Dimension	Score	Rationale
Scientific Novelty	7	MSS/pMMR CRC is paradigmatically refractory to ICI — finding OS benefit in a liver-met-negative subgroup is clinically significant and surprising
Clinical Relevance	7	If confirmed, reshapes treatment algorithm for a large chemorefractory population with limited options
Population Reach	7	Colorectal cancer is 3rd most common cancer globally; MSS accounts for ~95% of mCRC
Implementation Speed	5	Requires prospective validation before guideline change; but existing ICI drugs available
Evidence Strength	5	Retrospective propensity-matched; n=354 (177 per arm); selection bias risk; abstract only; hypothesis-generating

Quantitative result: ICI-based regimens yielded longer OS vs. SOC in chemorefractory pMMR/MSS mCRC without liver metastases (specific HR not reported in abstract) External validation: No external replication; consistent with mechanistic hypothesis about liver immune suppression Main limitation: Retrospective; potential selection bias; "without liver metastases" subgroup may not be representative; abstract only Equity: Benefits patients with a nearly untreatable cancer subtype who have exhausted standard options Evidence Maturity Revision: Exploratory (confirmed — hypothesis-generating; prospective trial needed urgently)

Phase 2 Composite Score: (7×0.30) + (7×0.25) + (7×0.20) + (5×0.15) + (5×0.10) = 6.50 Original triage_score: 7

Article 14 — PMID 42686334

Precision Oncology in Pediatric Cancer Surgery — Review 🟡

Dimension	Score	Rationale
Scientific Novelty	5	Review of a rapidly evolving field; synthesizes recent molecular-surgical integration
Clinical Relevance	5	Educational value for surgical oncologists; not primary data
Population Reach	5	Pediatric oncology affects ~17,000 children/year in US; relative rarity increases unmet need weight
Implementation Speed	3	Review article; implementation depends on underlying referenced evidence
Evidence Strength	2	Review, species unknown, no primary data, COI extraction artifact; abstract only; classification_confidence = high but limited extractable content

Phase 2 Composite Score: (5×0.30) + (5×0.25) + (5×0.20) + (3×0.15) + (2×0.10) = 4.50 Original triage_score: 7 (overcalled)

Article 15 — PMID 42686332

Precision Oncology in Melanoma — Review

Dimension	Score	Rationale
Scientific Novelty	4	Established field; review of known advances
Clinical Relevance	5	Useful synthesis for surgical oncologists
Population Reach	6	Melanoma incidence rising globally; metastatic melanoma prognosis transformed
Implementation Speed	4	Review; no new actionable finding beyond existing practice
Evidence Strength	2	Review only; no primary data

Phase 2 Composite Score: (5×0.30) + (6×0.25) + (4×0.20) + (4×0.15) + (2×0.10) = 4.70 Original triage_score: 7 (overcalled)

Article 16 — PMID 42686322

Evolution of Precision Oncology and Molecular Tumor Boards — Review

Dimension	Score	Rationale
Scientific Novelty	4	Overview of known field evolution
Clinical Relevance	5	Molecular tumor boards increasingly important for implementation
Population Reach	6	Cancer broadly
Implementation Speed	4	Educational; no direct intervention
Evidence Strength	2	Review; classification_confidence = low; COI artifact extracted as key finding

Phase 2 Composite Score: (5×0.30) + (6×0.25) + (4×0.20) + (4×0.15) + (2×0.10) = 4.70 Original triage_score: 7 (overcalled — low confidence, no primary data)

Article 17 — PMID 42686064

Dietary Glycemic Load and Chronic Disease Prevention — Review

Dimension	Score	Rationale
Scientific Novelty	4	Glycemic load and insulin demand are well-studied concepts
Clinical Relevance	5	Dietary guidance has broad application
Population Reach	8	Diabetes/metabolic disease affects billions
Implementation Speed	5	Dietary counseling deployable; adherence challenges
Evidence Strength	2	Review; classification_confidence = low; key finding extracted from title only

Phase 2 Composite Score: (5×0.30) + (8×0.25) + (4×0.20) + (5×0.15) + (2×0.10) = 5.25 Original triage_score: 7 (overcalled)

Article 18 — PMID 42685366

HFpEF-ABA Score for HFpEF Diagnosis in T2D Outpatients

Dimension	Score	Rationale
Scientific Novelty	5	New diagnostic score in T2D+HFpEF overlap — clinically important but incremental
Clinical Relevance	7	HFpEF is under-diagnosed in diabetic patients; score adds prognostic value
Population Reach	8	T2D affects 500M+ globally; HFpEF is common comorbidity
Implementation Speed	6	Clinical score easily implemented in outpatient settings
Evidence Strength	5	Prospective; n=190; moderate discrimination; abstract only; single-center

Quantitative result: HFpEF-ABA score showed moderate diagnostic discrimination and associated with adverse outcomes at follow-up External validation: Not reported; needs external validation cohort Main limitation: Single center; moderate AUC (not reported); abstract only; lacks validation for opportunistic screening (noted in population field) Equity: Applicable in outpatient cardiology/endocrinology; no specialized imaging required — equity positive Evidence Maturity Revision: Validated (confirmed — prospective data supports score development, though external validation pending)

Phase 2 Composite Score: (7×0.30) + (8×0.25) + (5×0.20) + (6×0.15) + (5×0.10) = 6.60 Original triage_score: 7

Article 19 — PMID 42684842

Cardiometabolic Risk After Hypertensive Disorders of Pregnancy — Review

Dimension	Score	Rationale
Scientific Novelty	5	HDP-CVD link established; optimization strategies are the novel focus
Clinical Relevance	6	Women post-HDP are under-monitored; actionable prevention message
Population Reach	7	Affects ~10% of all pregnancies globally
Implementation Speed	5	Requires postpartum follow-up infrastructure
Evidence Strength	3	Review; no primary data; abstract only

Phase 2 Composite Score: (6×0.30) + (7×0.25) + (5×0.20) + (5×0.15) + (3×0.10) = 5.65 Original triage_score: 7

Article 20 — PMID 42684836

Henagliflozin on Cardiac Structure in Dialysis Patients with HFpEF

Dimension	Score	Rationale
Scientific Novelty	7	SGLT2 inhibitors generally excluded from dialysis patients in major trials — first data in this gap
Clinical Relevance	7	HFpEF in dialysis patients is nearly untreatable; LVMI reduction is meaningful surrogate
Population Reach	5	~500,000 dialysis patients in US; globally ~3M — smaller but high-unmet-need population
Implementation Speed	5	Requires regulatory data in dialysis; small study needs replication
Evidence Strength	4	Small RCT/comparative study (n=56); design unspecified; abstract only; classification_confidence = medium

Quantitative result: Greater LVMI reduction at week 24 vs. placebo; tolerable safety profile External validation: None; very small study Main limitation: n=56; design unspecified (likely small RCT); short follow-up (24 weeks); abstract only Equity: Dialysis patients are often excluded from cardiovascular trials — this study directly addresses an equity gap Evidence Maturity Revision: Exploratory (confirmed — underpowered pilot at best)

Phase 2 Composite Score: (7×0.30) + (5×0.25) + (7×0.20) + (5×0.15) + (4×0.10) = 5.90 Original triage_score: 7

Article 21 — PMID 42684557

JAK Inhibitors Real-World Effectiveness in Rheumatoid Arthritis

Dimension	Score	Rationale
Scientific Novelty	4	JAKi in RA is established; real-world multicenter safety adds incremental evidence
Clinical Relevance	6	Real-world safety data addresses post-marketing concerns (especially CV risk)
Population Reach	7	RA affects ~1% of adults globally
Implementation Speed	7	JAKi already in use; findings immediately applicable to clinical decision-making
Evidence Strength	5	Multicenter cohort; n=440; short follow-up; underpowered for rare events (self-stated limitation); abstract only

Quantitative result: JAKi effective with acceptable safety profile; insufficient power for rare event detection External validation: Multicenter design; consistent with prior registry data Main limitation: Short follow-up; underpowered for rare CV and cancer events; observational; abstract only Equity: RA disproportionately affects women; Italian cohort may limit generalizability Evidence Maturity Revision: Validated (confirmed — consistent with broader registry literature)

Phase 2 Composite Score: (6×0.30) + (7×0.25) + (4×0.20) + (7×0.15) + (5×0.10) = 5.90 Original triage_score: 7

Article 22 — PMID 42685256

Benzodiazepine Use Blunts Lifestyle Intervention Efficacy in Frail Older Adults — RCT Secondary Analysis

Dimension	Score	Rationale
Scientific Novelty	6	Specific drug-lifestyle interaction in frailty prevention is novel and underappreciated
Clinical Relevance	8	Actionable message: deprescribe benzodiazepines to maximize exercise program benefit
Population Reach	7	Frail older adults are a large and growing population; benzodiazepine use is common
Implementation Speed	7	Deprescribing is a clinical behavior change — relatively rapid if guidance issued
Evidence Strength	6	Secondary analysis of SPRINTT RCT; n=1,506; high-quality base trial; secondary analysis limitations apply

Quantitative result: Benzodiazepine use significantly blunts effectiveness of lifestyle interventions for preventing mobility disability in frail older adults External validation: Derived from a well-conducted multicenter RCT (SPRINTT) Main limitation: Secondary analysis — not powered for this subgroup; confounding by indication (sicker patients on BZD); abstract only Equity: Older adults, particularly women, are disproportionate benzodiazepine users — important equity signal Evidence Maturity Revision: Potentially Practice-Changing (confirmed)

Phase 2 Composite Score: (8×0.30) + (7×0.25) + (6×0.20) + (7×0.15) + (6×0.10) = 7.00 Original triage_score: 7 — Phase 2 confirms and aligns

Article 23 — PMID 42686580

SLIM-TARGET: Weight Loss RCT for Obesity Management

Dimension	Score	Rationale
Scientific Novelty	4	Weight loss intervention research is mature; specific target-setting component is incremental
Clinical Relevance	6	Early BP improvement + motivation boost has practical implications
Population Reach	8	Obesity affects 1 billion+ globally
Implementation Speed	6	Behavioral interventions deployable in primary care
Evidence Strength	5	RCT; n=294; abstract provides limited quantitative detail; abstract only

Phase 2 Composite Score: (6×0.30) + (8×0.25) + (4×0.20) + (6×0.15) + (5×0.10) = 6.00 Original triage_score: 7

Article 24 — PMID 42686471

CBCT vs. Panoramic Radiography for IAN Localization in BSSRO

Dimension	Score	Rationale
Scientific Novelty	4	CBCT vs. panoramic for nerve localization is established comparison
Clinical Relevance	5	Relevant to oral/maxillofacial surgeons
Population Reach	3	Narrow specialty population
Implementation Speed	5	CBCT adoption ongoing
Evidence Strength	3	Design unspecified; no sample size; abstract only; classification_confidence = medium

Phase 2 Composite Score: (5×0.30) + (3×0.25) + (4×0.20) + (5×0.15) + (3×0.10) = 4.10 Original triage_score: 7 (significant overcall — narrow specialty, limited extractable data)

Article 25 — PMID 42686455

Nurse Navigation Program for Lung Cancer Patients — RCT

Dimension	Score	Rationale
Scientific Novelty	4	Nurse navigation in oncology is established; RCT evidence in NSCLC adds rigor
Clinical Relevance	7	Reduces depression, anxiety, improves QoL in newly diagnosed NSCLC — high impact on patient experience
Population Reach	7	Lung cancer is most lethal cancer globally; 2M+ new diagnoses/year
Implementation Speed	7	Nursing program deployable with training; no technology barrier
Evidence Strength	4	RCT; but n=42 is very small; limited statistical power; abstract only

Quantitative result: LungCaNN reduced depression, stress, anxiety; improved chronic disease adaptation and QoL in newly diagnosed NSCLC External validation: Small single-center RCT; needs replication Main limitation: Very small n (42); single center; short follow-up; abstract only Equity: Nurse navigation is relatively low-cost and scalable — equity positive Evidence Maturity Revision: Potentially Practice-Confirming (concept well-established; this RCT adds formal evidence)

Phase 2 Composite Score: (7×0.30) + (7×0.25) + (4×0.20) + (7×0.15) + (4×0.10) = 6.20 Original triage_score: 7

Article 26 — PMID 42686359

Erector Spinae Plane Block for Post-Breast Reconstruction Pain — RCT

Dimension	Score	Rationale
Scientific Novelty	5	ESPB in breast surgery is an active research area; perineural dexmedetomidine addition is incremental novelty
Clinical Relevance	7	Reduces opioid requirements and improves recovery — directly actionable for anesthesiology
Population Reach	6	Breast reconstruction surgery common; opioid sparing has broad relevance
Implementation Speed	7	Regional anesthesia technique deployable with training; no new equipment
Evidence Strength	5	RCT; no sample size reported; abstract only

Phase 2 Composite Score: (7×0.30) + (6×0.25) + (5×0.20) + (7×0.15) + (5×0.10) = 6.20 Original triage_score: 7

Articles 27–65 — Summary Scores (lower-priority batch)

#	PMID	Brief Title	Clinical Rel	Pop Reach	Sci Nov	Impl Speed	Evid Str	Composite
27	42686569	CMV enterocolitis post-myeloma chemo (case)	4	3	3	2	2	3.20
28	42686439	Prostate lymphoma systematic review	5	3	3	5	4	4.20
29	42686335	Lymphoma/Myeloma management for surgeons (review)	4	4	3	2	2	3.40
30	42685709	Parkinson's/Alzheimer's biological subtyping	5	6	5	5	4	5.10
31	42684705	Historical redlining & breast cancer screening	5	6	6	4	5	5.30
32	42685242	SEVMALrisk validated malaria severity score	5	5	5	6	6	5.25
33	42684816	PI-QUAL for prostate MRI quality (review)	5	5	3	5	3	4.50
34	42684674	MoodMon AI for affective disorders	5	6	5	4	4	5.00
35	42686331	Precision oncology in HPB surgery (review)	4	4	4	3	2	3.70
36	42686329	Precision oncology in lung cancer surgery (review)	4	5	4	3	2	3.85
37	42686325	Tissue-agnostic therapy approvals (review)	5	6	5	3	2	4.45
38	42686572	Nivolumab + FOLFOX complete response gastric (case)	4	4	5	3	1	3.70
39	42686327	Perioperative risks immunotherapy (review; low conf.)	4	5	4	3	2	3.85
40	42685699	Cyclin E-CDK2 & immunotherapy response	3	4	6	2	4	3.70
41	42684528	MASLD in aging population (review)	4	6	4	3	2	4.10
42	42684403	DNA damage response and aging paradox	3	5	5	1	2	3.50
43	42685974	BRIC first case Cambodia (case report)	3	2	4	2	1	2.65
44	42685651	Nitisinone metabolic profiling in AKU	4	2	4	3	3	3.35
45	42684977	TSH elevation revealing adrenal insufficiency (case)	4	3	3	4	3	3.55
46	42686560	Bempedoic acid pharmacology review (Japanese)	5	6	4	3	3	4.60
47	42686453	Confluent glands predict concurrent AEH carcinoma	5	4	5	5	5	4.85
48	42686405	Otitis media with effusion in children (review)	4	5	3	4	2	3.85
49	42685812	Bayesian flow cytometry cell assignment (LBC-flow)	4	4	5	4	3	4.10
50	42686323	Landscape of molecular testing (review; low conf.)	4	5	3	4	2	3.85
51	42686225	Magnetic EV enrichment for prostate cancer proteomics	3	4	5	2	2	3.35
52	42685611	AI in cancer diagnosis and therapy review	4	6	3	4	3	4.10
53	42685374	Cost-effectiveness AB-MRI vs. CEM dense breasts	5	5	4	4	4	4.65
54	42685313	DNAmBERT: transformer for non-invasive cancer dx	4	6	6	3	3	4.50
55	42684448	TNM classification melanoma evolution (review)	4	5	4	3	2	3.85
56	42684409	Twitter discussions about cancer screening	3	5	3	4	3	3.55
57	42686375	RAB31/CME pathway in tumor immunology (animal)	2	3	6	1	3	2.90
58	42685867	Oral propionate in peanut OIT (preclinical)	3	4	6	1	2	3.35
59	42685688	MAIT cell therapy for HCC (preclinical)	3	4	7	1	2	3.45
60	42685608	3-MST inhibition enhances CD8+ antitumor immunity	3	4	6	2	3	3.55
61	42686519	Group chat competitiveness and exercise performance	3	4	4	5	3	3.65
62	42686275	SCI epidemiology review	3	5	3	2	2	3.20
63	42686181	Outcome measures in patellofemoral pain	3	4	3	3	3	3.25
64	42686537	Mastitis risk in dairy cows (non-human/animal)	1	1	3	2	3	1.70
65	42685567	EV isolation on capillary-channeled polymer columns	2	2	3	1	2	2.10

Phase 3 Ranking

Conflict Summary

No direct evidentiary conflicts were identified in this batch. Articles 4 (PMID 42686451) and prior ZUMA-7 data are directionally consistent (CAR-T > allo-HCT). Article 13 (PMID 42686374) — ICI benefit in MSS mCRC — is hypothesis-generating and contrasts with the widely-held paradigm that MSS CRC is ICI-resistant; this finding is preliminary and should not be interpreted as contradicting prior large trial data, but as identifying a potential subgroup exception warranting prospective investigation.

Ranked Impact Table

Rank	PMID	Title (Short)	Flag	Impact Score	Clin Rel (30%)	Pop Reach (25%)	Sci Nov (20%)	Impl Speed (15%)	Evid Str (10%)	Triage Score	Study Design	Why It Matters
1	42685256	Benzodiazepines blunt frailty prevention	⚪	7.00	8	7	6	7	6	7	RCT (secondary analysis)	Benzodiazepine use is common, deprescribing is immediately actionable, and the finding that it undermines exercise-based mobility disability prevention in frail older adults has direct clinical implications without requiring new drugs or technology. The SPRINTT trial base is rigorous and well-powered.
2	42686374	ICI benefit in MSS mCRC (no liver mets)	⚪	6.50	7	7	7	5	5	7	Retrospective propensity-matched	If confirmed, this would be the first signal that immunotherapy can extend OS in MSS colorectal cancer — a population with virtually no ICI options. The liver-metastasis-negative subgroup hypothesis is mechanistically plausible (hepatic immune suppression). High scientific novelty for an urgent unmet need.
3	42685984	HCC surveillance: MRI, biomarkers, stratification	🔴	6.50	7	8	6	5	4	7	Review/Perspective	Reaches an exceptionally large at-risk population (100M+ with cirrhosis globally). The synthesis of abbreviated MRI + biomarker stratification frames the next generation of HCC surveillance, with the PREMIUM RCT underway. Actionable today as guidance for which patients most benefit from intensified screening.
4	42685366	HFpEF-ABA Score in T2D outpatients	⚪	6.60	7	8	5	6	5	7	Prospective study	(Tie-broken by Clinical Relevance over #3) HFpEF is massively underdiagnosed in diabetic patients. A validated outpatient score requiring no specialized imaging could change how cardiologists and endocrinologists screen this population. Reaches the enormous T2D-HFpEF overlap pool.
5	42686451	CAR-T vs. allo-HCT for r/r LBCL	🟠	6.40	8	6	5	6	5	7	Cohort study	Real-world confirmation that axi-cel outperforms allo-HCT in a chemorefractory population, with lower treatment mortality as the key driver. Relevant to hematologists choosing between two established but competing strategies. Access equity remains a major barrier.
6	42686580	SLIM-TARGET weight loss RCT	⚪	6.00	6	8	4	6	5	7	RCT	Large population reach (obesity pandemic); early BP improvement boosting patient motivation is a practically useful finding for primary care. Limited by incomplete abstract reporting.
7	42684200	AI suicide risk prediction from EHR	⚪	6.00	6	8	6	4	4	7	Retrospective	AI-powered suicide risk stratification addresses one of medicine's most urgent unmet needs. Large population reach. Needs prospective validation and equity auditing before deployment.
8	42685390	Food insecurity and cancer outcomes meta-analysis	⚪	6.00	6	9	5	3	6	7	Systematic review/meta-analysis	Largest pooled dataset (n=1.1M) showing food insecurity systematically undermines cancer screening and treatment adherence. Foundational evidence for integrating food security screening into oncology workflows and policy.
9	42684836	Henagliflozin for HFpEF in dialysis patients	⚪	5.90	7	5	7	5	4	7	Small RCT/comparative	Fills a critical evidence gap — dialysis patients with HFpEF are excluded from standard SGLT2 trials. LVMI reduction is a meaningful structural endpoint. Highly preliminary but addresses a population with zero proven cardiac therapies.
10	42684557	JAK inhibitors real-world RA safety	⚪	5.90	6	7	4	7	5	7	Multicenter cohort	Adds real-world safety confirmation for JAKi in RA, directly relevant to prescribers navigating post-marketing safety concerns. Large population (RA affects millions); findings actionable today.
11	42686030	3D guides vs. robotics in spinal surgery NMA	⚪	5.30	6	5	4	5	5	7	Systematic review/NMA	NMA comparing three technology modalities for pedicle screw accuracy provides comparative evidence for surgical technology purchasing and training decisions.
12	42684491	Cornea-specialized LLM for diagnosis	⚪	5.80	6	4	7	6	6	7	RCT	One of the few RCTs testing a domain-specific LLM+RAG system in clinical practice. Proof-of-concept that AI can narrow expertise gaps in specialty medicine.
13	42686628	Non-pharm delirium prevention ICU RCT	⚪	5.80	6	6	4	6	6	8	Cluster RCT	Cluster RCT protocol for nurse-driven delirium prevention bundles. Important for ICU quality improvement but concept is established; triage score of 8 was substantially overcalled.
14	42686461	RFA vs. resection for small HCC in elderly	⚪	5.95	7	6	5	7	4	8	Propensity-matched cohort	Clinically meaningful treatment comparison for elderly HCC patients often excluded from trials. RFA's comparable oncologic outcomes with lower morbidity is practice-relevant, but small n limits confidence.
15	42684842	Cardiometabolic risk post-HDP review	⚪	5.65	6	7	5	5	3	7	Review	Important population health message for postpartum CVD prevention; limited by review-only design.
16	42685840	sPD-L1/sPD-1 biomarkers in NSCLC	⚪	5.65	6	7	6	4	3	7	Review	Blood-based immunotherapy monitoring has strong clinical appeal; needs prospective validation trials.
17	42686455	Nurse navigation for lung cancer QoL RCT	⚪	6.20	7	7	4	7	4	7	RCT	(Ranked here for small n=42 limiting confidence) Clinically meaningful QoL intervention; needs replication at scale.
18	42686359	Erector spinae block for breast reconstruction	⚪	6.20	7	6	5	7	5	7	RCT	Opioid-sparing regional anesthesia directly actionable for anesthesiology practice; missing sample size weakens confidence.
19	42685709	Biological Parkinson's subtype: aggressive progression	⚪	5.10	5	6	5	5	4	6	Cohort	Biologically defined Parkinson's subtypes improve prognostic precision; linked to hematologic malignancies topic incorrectly but finding is neurology-relevant.
20	42684705	Historical redlining & breast screening gaps	⚪	5.30	5	6	6	4	5	6	Cohort	JAMA Network Open publication; quantifies a persistent structural barrier to breast cancer screening. Important for health equity policy but limited clinical actionability.

Articles ranked below 20 (scores ≤ 4.85) are included in Phase 2 summary table above and are available on request.

Deep dive 1 Non-Pharm ICU Delirium Prevention RCT Protocol PMID 42686628 ↗

[HOOK]

Every day in intensive care units around the world, patients wake up confused, terrified, and completely disconnected from reality. Delirium — a sudden state of severe mental confusion — affects up to 80% of critically ill patients on mechanical ventilation. It's not just distressing in the moment. Delirium is independently linked to longer hospital stays, cognitive decline that can persist for years, and increased mortality. And for decades, we've been reaching for medications to treat it — with limited success.

[THE DISCOVERY]

This French multicenter cluster randomized controlled trial (Crozes et al.) is testing whether structured, nurse-driven non-pharmacological interventions can actually prevent delirium from developing in the first place. The protocol enrolls 474 ICU patients across multiple French intensive care units and systematically tests whether a coordinated bundle of non-drug strategies — including sleep hygiene protocols, early mobilization, reorientation cues, sensory optimization (lighting, noise reduction), and family involvement — can meaningfully reduce delirium incidence. Think of it like building a better ICU environment, systematically and rigorously, rather than waiting for delirium to appear and then trying to reverse it.

[THE SCIENCE BEHIND IT]

The cluster RCT design is the right tool here — it randomizes entire ICU units rather than individual patients, which is appropriate when the intervention is a ward-level protocol that can't be blinded at the patient level. The sample size of 474 provides reasonable power. This approach aligns with international ICU care frameworks (including the well-known ABCDEF bundle), which have growing observational support but fewer rigorous randomized confirmations. The key limitation is significant: this article is a protocol paper in a French nursing journal, available only as an abstract in French. We cannot evaluate primary outcome data — those won't exist until the trial completes. The score of 8 assigned by the triage pipeline reflects the RCT design; the Phase 2 score of 5.80 reflects that we are evaluating a protocol, not results.

[WHO THIS HELPS]

ICU patients — particularly elderly individuals and those on mechanical ventilation — are the primary beneficiaries. Nurses and bedside care teams are the implementers. Critically, this is an intervention that doesn't require new drugs, new devices, or major capital expenditure — it requires coordinated nursing care, which makes it potentially applicable even in resource-constrained settings.

[THE REAL-WORLD IMPACT]

If the trial shows benefit, the implications are meaningful for workflow. ICU teams would have randomized evidence to support formalized delirium prevention bundles as standard of care — not just best-practice recommendations, but trial-proven protocols. This could reduce ICU length of stay (delirium extends ICU stays by an average of 2–3 days per episode) and may reduce long-term cognitive impairment, which affects up to 30% of ICU survivors. Cost implications would be favorable: nursing protocols cost less than ICU-days or post-discharge cognitive rehabilitation.

[WHAT WE STILL DON'T KNOW]

We don't yet have the results. The intervention's effectiveness may differ significantly by ICU type, patient acuity, staffing levels, and hospital culture. Even if effective in French ICUs, implementation fidelity in other healthcare systems is uncertain. The French-language publication also limits international visibility and uptake.

[LIKELIHOOD OF MAKING A DIFFERENCE]

Scientific Confidence: Moderate (strong design; concept plausible; no results yet)
Translation Speed: 2–5 years (trial completion + guideline integration)
Barrier Analysis:
- Regulatory: None — behavioral intervention
- Reimbursement: None required; may need staffing investment
- Cost: Low capital; requires training time and sustained staff engagement
- Infrastructure: Requires sufficient nursing staff ratios — a real constraint in many systems
- Awareness: Currently limited by French-language publication; English dissemination needed
- Equity: Underfunded or understaffed ICUs face implementation barriers — equity gap likely

[CALL TO ACTION / CLOSING]

The most powerful ICU intervention may not come in a syringe. Watch for the results of this trial — and in the meantime, ICU teams can start with what the evidence already supports: protecting sleep, getting patients moving, and keeping family close.

Deep dive 2 RFA vs. Laparoscopic Resection for Small HCC in Elderly Patients PMID 42686461 ↗

[HOOK]

Liver cancer is the third leading cause of cancer death worldwide — and its most common form, hepatocellular carcinoma, disproportionately strikes older adults with underlying liver disease. When an elderly patient has a single small tumor and their surgeon asks "should we operate or ablate?", that question rarely has a clean evidence-based answer. Until now, most trials on this comparison excluded the very patients most likely to face it.

[THE DISCOVERY]

This multicenter propensity score-matched study (Yang et al.) compared radiofrequency ablation — a minimally invasive technique that uses heat to destroy tumors — against laparoscopic liver resection in elderly patients with a single small hepatocellular carcinoma. The key finding: for tumors 2 centimeters or smaller, or in patients with elevated surgical risk, radiofrequency ablation achieved comparable overall survival while delivering significantly lower complication rates and faster recovery. The cancer control was equivalent; the patient experience was meaningfully better.

[THE SCIENCE BEHIND IT]

The study used propensity score matching to balance the two groups across 102 patients from multiple centers — an appropriate but imperfect method for reducing selection bias in a non-randomized comparison. The multicenter design improves generalizability over single-center reports. However, the sample size of 102 is small — likely around 51 per arm post-matching — and this is an observational study, not a randomized trial. That means unmeasured confounders could explain some of the findings. Elderly patients selected for surgery may have been systematically fitter than those selected for ablation, which would artificially favor the resection arm. The fact that outcomes were similar despite this potential bias actually strengthens the case for ablation. Classification confidence was rated medium, and the full text is unavailable. Main limitation: small n, retrospective design, unknown follow-up duration, abstract only.

[WHO THIS HELPS]

Elderly patients with small hepatocellular carcinoma — particularly those with cirrhosis, reduced functional reserve, or comorbidities that elevate surgical risk. This is a population that has historically been either undertreated (deemed too fragile for surgery) or overtreated (pushed through surgery with high complication rates). The study also matters to surgeons and hepatologists who counsel patients on treatment choices, and to tumor boards weighing the trade-off between oncologic completeness and procedural safety.

[THE REAL-WORLD IMPACT]

If adopted into practice guidelines, this finding would shift the default treatment recommendation for elderly patients with HCC ≤2 cm from laparoscopic resection toward radiofrequency ablation in appropriate candidates. Shorter hospital stays, fewer complications, and faster return to baseline function are concrete benefits. Radiofrequency ablation is widely available in hepatology centers globally, so implementation does not require new infrastructure. The cost savings from shorter hospitalization and fewer post-operative complications could be substantial at population scale.

[WHAT WE STILL DON'T KNOW]

The critical unknown is long-term recurrence. Radiofrequency ablation has higher local recurrence rates than resection for tumors above 2 cm, and for tumors near major vessels. Whether equivalent OS at this study's follow-up period holds at 5 and 10 years is unknown. The optimal tumor size threshold — where resection's advantage becomes clinically meaningful — needs prospective definition. We also don't know how these findings apply to elderly patients with more advanced cirrhosis or specific tumor locations.

[LIKELIHOOD OF MAKING A DIFFERENCE]

Scientific Confidence: Moderate (consistent with prior literature direction; limited by small n and observational design)
Translation Speed: 2–5 years (needs larger prospective study or RCT confirmation; some guidelines may already be moving in this direction)
Barrier Analysis:
- Regulatory: None — both techniques are approved
- Reimbursement: Ablation is generally reimbursed; may actually reduce costs
- Cost: RFA is less expensive than open or laparoscopic resection — favorable economics
- Infrastructure: RFA available in most hepatology centers; interventional radiology or hepatology training required
- Awareness: Surgeon culture may favor resection; changing intraoperative mindset requires education
- Equity: Elderly patients and those with comorbidities are often underrepresented in trials; this study directly addresses that gap

[CALL TO ACTION / CLOSING]

For elderly patients with a small liver tumor, the question isn't just "can we operate?" — it's "should we?" This study adds real-world evidence that for the right patient, less is genuinely more: equivalent cancer control, with a body that has more left to give.